相关实验视频

Updated: May 10, 2025

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

甲用于治疗化疗诱导的外围神经病变 (METACIN):研究协议

Mathieos Belayneh^1,2, Samar Hejazi³, Bruno Gagnon^4,5

¹Division of Palliative Care, Department of Medicine, University of British Columbia, Vancouver, Canada.

Pain management

|April 28, 2025

概括

甲可能是化疗诱导的周围神经病变 (CIPN) 的有效治疗方法,这是癌症疼痛的常见原因. 这项研究将甲与duloxetine对CIPN患者进行比较,为这种痛苦的疾病提供了一个新的选择.

科学领域:

在瘤学瘤学.
神经学神经学
药理学药理学是指药理学的学科.

背景情况:

慢性化疗诱导的周围神经病变 (CIPN) 影响70%的癌症患者,导致神经病痛.
杜洛西丁是标准的治疗方法,但对耐火性神经病性癌症疼痛有效的甲是CIPN的研究不足.
对于这种常见而使人衰弱的疾病,治疗选择有限.

研究的目的:

为了确定甲是否是一种可行的治疗CIPN.
为了比较甲与杜洛西丁在降低CIPN患者疼痛强度方面的疗效.

主要方法:

一个三重盲目的,双模拟的随机对照试验.
成年癌症患者>1级CIPN持续≥3个月被随机分配给甲或杜洛西丁.
每周随访5周,剂量定位;24周随访不良事件和剂量升级.

主要成果:

主要结局:甲与杜洛西丁在从基线到研究结束的平均疼痛强度降低方面的有效性.
二次结果:改善功能干扰和生活质量.
探索性结果:疼痛减缓值 (≥30%或≥50%),患者报告的总体变化印象,不良事件和甲剂量升级.

结论:

这项研究将提供关于甲作为CIPN治疗的疗效和安全性的关键数据.
这些发现可以扩大患有CIPN.癌症的癌症患者的治疗选择.
结果将为临床实践和管理CIPN.指南提供信息.

关键词:

甲顿是一种甲.这是一种NMDA抗剂.这是SNRI的SNRI.癌症疼痛疼痛癌症疼痛化学疗法化疗化疗杜洛克赛丁 (duloxetine) 是一种药物.这是一种神经病的精神病.周围神经病变 (Peripheral Neuropathy) 是一种神经病变.

更多相关视频

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities

Published on: July 29, 2014

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...